We hypothesized that gadoxetate disodium-enhanced MRI may provide additional prognostic information and we aimed to evaluate use of gadoxetate disodium to image prostate cancer and to track its utility as a biomarker for non-invasive assessment of the expression of OATP1B3 in prostate tumors. The gene discussed is SLCO1B3; the disease is Familial prostate cancer.